The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease

Ilya Berim, Sanjay Sethi

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major contributors to the morbidity and mortality associated with this disease. Current approaches that likely reduce chronic obstructive pulmonary disease (COPD) exacerbations include smoking cessation, influenza and pneumococcal vaccinations, long-acting bronchodilator and inhaled corticosteroid therapy, pulmonary rehabilitation, and mucolytic drugs. However, with optimal treatment using all of these modalities, we are only able to reduce exacerbations by about 40%. A significant proportion of COPD exacerbations are bacterial, therefore long-term antimicrobial therapy could have a role in preventing exacerbations. Long-term antibiotic treatment in COPD regimens that are being evaluated include low-dose macrolide therapy, pulsed fluoroquinolone administration and the use of inhaled antibiotics. Although initial results have been promising with significant reductions in exacerbations with these regimens, additional studies are required to identify the appropriate patient and regimen and elucidate the risk-benefit as well as cost effectiveness of long-term antibiotics in COPD.

Original languageEnglish
Pages (from-to)207-216
Number of pages10
JournalTherapeutic Advances in Respiratory Disease
Volume5
Issue number3
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Chronic Obstructive Pulmonary Disease
Anti-Bacterial Agents
Disease Progression
Expectorants
Therapeutics
Bronchodilator Agents
Fluoroquinolones
Macrolides
Smoking Cessation
Human Influenza
Cost-Benefit Analysis
Adrenal Cortex Hormones
Vaccination
Rehabilitation
Morbidity
Lung
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease. / Berim, Ilya; Sethi, Sanjay.

In: Therapeutic Advances in Respiratory Disease, Vol. 5, No. 3, 06.2011, p. 207-216.

Research output: Contribution to journalReview article

@article{bf1cfaa73c074dccae25780e4b14e62a,
title = "The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease",
abstract = "Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major contributors to the morbidity and mortality associated with this disease. Current approaches that likely reduce chronic obstructive pulmonary disease (COPD) exacerbations include smoking cessation, influenza and pneumococcal vaccinations, long-acting bronchodilator and inhaled corticosteroid therapy, pulmonary rehabilitation, and mucolytic drugs. However, with optimal treatment using all of these modalities, we are only able to reduce exacerbations by about 40{\%}. A significant proportion of COPD exacerbations are bacterial, therefore long-term antimicrobial therapy could have a role in preventing exacerbations. Long-term antibiotic treatment in COPD regimens that are being evaluated include low-dose macrolide therapy, pulsed fluoroquinolone administration and the use of inhaled antibiotics. Although initial results have been promising with significant reductions in exacerbations with these regimens, additional studies are required to identify the appropriate patient and regimen and elucidate the risk-benefit as well as cost effectiveness of long-term antibiotics in COPD.",
author = "Ilya Berim and Sanjay Sethi",
year = "2011",
month = "6",
doi = "10.1177/1753465811398372",
language = "English",
volume = "5",
pages = "207--216",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease

AU - Berim, Ilya

AU - Sethi, Sanjay

PY - 2011/6

Y1 - 2011/6

N2 - Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major contributors to the morbidity and mortality associated with this disease. Current approaches that likely reduce chronic obstructive pulmonary disease (COPD) exacerbations include smoking cessation, influenza and pneumococcal vaccinations, long-acting bronchodilator and inhaled corticosteroid therapy, pulmonary rehabilitation, and mucolytic drugs. However, with optimal treatment using all of these modalities, we are only able to reduce exacerbations by about 40%. A significant proportion of COPD exacerbations are bacterial, therefore long-term antimicrobial therapy could have a role in preventing exacerbations. Long-term antibiotic treatment in COPD regimens that are being evaluated include low-dose macrolide therapy, pulsed fluoroquinolone administration and the use of inhaled antibiotics. Although initial results have been promising with significant reductions in exacerbations with these regimens, additional studies are required to identify the appropriate patient and regimen and elucidate the risk-benefit as well as cost effectiveness of long-term antibiotics in COPD.

AB - Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major contributors to the morbidity and mortality associated with this disease. Current approaches that likely reduce chronic obstructive pulmonary disease (COPD) exacerbations include smoking cessation, influenza and pneumococcal vaccinations, long-acting bronchodilator and inhaled corticosteroid therapy, pulmonary rehabilitation, and mucolytic drugs. However, with optimal treatment using all of these modalities, we are only able to reduce exacerbations by about 40%. A significant proportion of COPD exacerbations are bacterial, therefore long-term antimicrobial therapy could have a role in preventing exacerbations. Long-term antibiotic treatment in COPD regimens that are being evaluated include low-dose macrolide therapy, pulsed fluoroquinolone administration and the use of inhaled antibiotics. Although initial results have been promising with significant reductions in exacerbations with these regimens, additional studies are required to identify the appropriate patient and regimen and elucidate the risk-benefit as well as cost effectiveness of long-term antibiotics in COPD.

UR - http://www.scopus.com/inward/record.url?scp=79957862673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957862673&partnerID=8YFLogxK

U2 - 10.1177/1753465811398372

DO - 10.1177/1753465811398372

M3 - Review article

VL - 5

SP - 207

EP - 216

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 3

ER -